R Chambers - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

R Chambers

Showing results (481-490 of 483) with videos related to

Pageof 49

Sort By:

You have reached the last page of results.This site can display upto 483 results.

Nature Cancer|August 28, 2023

A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancerJessica L Chitty, Michelle Yam, Lara Perryman, et al.

Science Advances|March 12, 2025

Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasisCecilia R Chambers, Supitchaya Watakul, Peter Schofield, et al.

Science Advances|July 3, 2024

Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy responseBrooke A Pereira, Shona Ritchie, Cecilia R Chambers, et al.

Pageof 49

Search research articles

Showing results (481-490 of 483) with videos related to

Sort By:

Pageof 49

You have reached the last page of results.This site can display upto 483 results.

Nature Cancer|August 28, 2023

A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancerJessica L Chitty, Michelle Yam, Lara Perryman, et al.

Science Advances|March 12, 2025

Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasisCecilia R Chambers, Supitchaya Watakul, Peter Schofield, et al.

Science Advances|July 3, 2024

Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy responseBrooke A Pereira, Shona Ritchie, Cecilia R Chambers, et al.

Pageof 49